Insulet Corporation $PODD Shares Sold by Curated Wealth Partners LLC

Key Points

• Curated Wealth Partners cut its Insulet stake by 83.4% in the third quarter, selling 12,400 shares and retaining 2,464 shares valued at approximately $321,000.
• Institutional interest was mixed: BlackRock, Man Group, Bank of America and Bank of New York Mellon initiated positions, while Arrowstreet Capital increased its holdings by 462.7%.
• Insulet reported quarterly EPS of $1.66 and revenue of $801.7 million, beating estimates and posting 23.5% year-over-year revenue growth. Analysts’ consensus rating is Hold, with an average price target of $186.68 versus a recent share price of $141.10.

Curated Wealth Partners LLC lessened its holdings in shares of Insulet Corporation (NASDAQ:PODD - Free Report) by 83.4% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,464 shares of the medical instruments supplier's stock after selling 12,400 shares during the period. Curated Wealth Partners LLC's holdings in Insulet were worth $321,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. BlackRock Inc. acquired a new stake in shares of Insulet during the 2nd quarter worth approximately $1,018,582,000. Arrowstreet Capital Limited Partnership boosted its position in Insulet by 462.7% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier's stock valued at $258,088,000 after purchasing an additional 1,011,369 shares during the period. Man Group plc acquired a new position in Insulet during the 2nd quarter valued at approximately $78,746,000. Bank of America Corp DE acquired a new position in Insulet during the 2nd quarter valued at approximately $64,921,000. Finally, Bank of New York Mellon Corp bought a new position in Insulet during the 2nd quarter worth $60,615,000.

Analysts Set New Price Targets

Several brokerages have weighed in on PODD. Benchmark dropped their target price on Insulet from $250.00 to $185.00 and set a "buy" rating on the stock in a research report on Thursday, August 6th. Citigroup raised their target price on Insulet from $165.00 to $172.00 and gave the company a "neutral" rating in a research note on Wednesday, July 8th. Robert W. Baird set a $175.00 price target on shares of Insulet in a report on Thursday, August 6th. Canaccord Genuity Group lowered their price target on shares of Insulet from $249.00 to $179.00 and set a "buy" rating for the company in a research report on Thursday, August 6th. Finally, BTIG Research lowered shares of Insulet from a "buy" rating to a "neutral" rating in a research report on Thursday, August 6th. Thirteen analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $186.68.

Insulet Stock Performance

Shares of PODD stock opened at $141.10 on Friday. Insulet Corporation has a 12-month low of $126.40 and a 12-month high of $354.88. The firm has a market capitalization of $9.79 billion, a price-to-earnings ratio of 26.37, a price-to-earnings-growth ratio of 1.11 and a beta of 1.11. The business has a 50 day simple moving average of $140.56 and a 200 day simple moving average of $156.82. The company has a debt-to-equity ratio of 0.65, a current ratio of 2.48 and a quick ratio of 1.83.

Insulet (NASDAQ:PODD - Get Free Report) last posted its earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 EPS for the quarter, beating the consensus estimate of $1.47 by $0.19. The firm had revenue of $801.70 million for the quarter, compared to analysts' expectations of $787.39 million. Insulet had a return on equity of 29.29% and a net margin of 12.29%. The firm's revenue was up 23.5% compared to the same quarter last year. During the same period last year, the firm earned $1.17 EPS. Insulet has set its FY 2026 guidance at 6.460- EPS. On average, equities research analysts anticipate that Insulet Corporation will post 6.51 EPS for the current year.

About Insulet

Insulet Corporation is a medical device company that develops, manufactures and markets wearable insulin delivery systems for people with diabetes. The company is best known for its Omnipod platform, which is designed to provide insulin delivery without the tubing traditionally associated with conventional insulin pumps.

Insulet's product portfolio includes the Omnipod 5 Automated Insulin Delivery System, a tubeless, wearable system that integrates with continuous glucose monitoring technology to automate insulin delivery, as well as the Omnipod DASH system.

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.